.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You've been posting old clippings from the article. Please reread the article as it's been changed since early yesterday.
Read Article Here
I suggest you reread that section as I've added/changed parts of it to make my point more obvious. Given that section did make the information more dier then it actually is.
Okay. What do you want to resolve about it?
@JohnCM Did you send me a message? I didn't get it if so. Are you referring to the cannabis thing you're talking about?
RXMD Article
MediaG3, Inc. (MDGC) Forward-Looking Analysis
Read Full Article Here!
MediaG3, Inc.
Ticker: MDGC
PPS: 0.0011 a/o 8/13/2017
Up 0.0005 or (+83.33%)
Address:
1501 South Federal Way
Boise, Idaho 83705
United States
208-321-4188
Market Value: $1,642,860 a/o August 11, 2017
Authorized Shares: 1,500,000,000 a/o June 30, 2013
Outstanding Shares: 1,493,509,343 a/o June 30, 2013
Float: 1,190,769,673 a/o June 30, 2013
Fundamental Analysis:
According to Reuters, MediaG3, Inc. is engaged in the designing, developing, and deploying of wireless broadband internet, wireless networks, fixed and mobile internet, communications, media, and entertainment products and services for individuals and companies of all sizes. The company’s products include broadband wireless access base stations and customer premises equipment for fixed and mobile point-to-point digital microwave radio systems for internet access.
MediaG3 Management:
Mr. William Yuan, Founder
Dr. Robert P. McNamara Ph.D., Technology Advisor
Mr. Steven Keating, Financial Advisor
Mr. Val Westergard, Chairman, and Chief Technology Officer
Byron Ryals, Vice Chairman, and Chief Executive Officer
Statistics:
Market Cap (Intraday) 1.65M
Trailing P/E: -1.10
Beta: -169.88
52-Week High: 0.0011
52-Week Low: 0.00006
50-Day Moving Average: 0.0005
200-Day Moving Average: 0.0002
Average Volume (3 Month): 6.33M
Average Volume (10 Day): 31.88M
On August 9, 2017, news broke titled, “International Venture Society Presents the Following Shareholder Updates (OTC PINK: GRDO, MSMY, MDGC).” International Venture Society has been in talks with the court about creating a state charter revival, company reconstruction plan, and to find possible merger candidates as well as to get these companies to meet regulatory compliance.
“I am hopeful that the stockholders of the individual companies will view the courts' decision as a vital first step for International Venture Society to construct these long non-operational OTC companies into legitimate businesses once again,” stated International Venture Society CEO Kelani Long.
Read Full Article Here!
I'm pretty sure this stock is dead. Any news from the SEC?
If you guys would like, I could totally do a new article discussing the income and balance statements from the annual report.
Read The Full Article Here!
MC Endeavors, Inc.
Ticker Symbol: MSMY
PPS: 0.0013 a/o 8/12/17
Up 0.0006 or %85.71
According to Reuters, MC Endeavors is a global smart-home builder and self-sustaining community developer of natural disaster resistant building systems that utilize steel framing or steel shipping containers with rigid closed-cell foam insulation instead of conventional wood framing and rolled fiberglass.
Company Management:
Mr. Timothy L. Algier, Chief Executive Officer (CEO), President and Director
Mr. Joshua Graham, Chief Operating Officer (COO) and Director
Ricki Groetzmeier, Sec., Treasurer and Director
Israel Sanchez, Director of Design Devel
Statistics:
Market Cap (Intraday): 310.55k
Price/Sales: 2.13
Beta: -3.22
52-Week Change: 133.33%
52-Week High: 0.0015
52-Week Low: 0.0002
50-Day Moving Average: 0.0007
200-Day Moving Average: 0.0007
Average Volume (3 Months): 596.53k
Average Volume (10 Day): 3.1M
Shares Outstanding: 238.88M
Float: Unknown
NO OTC Filing (DANGER)
NO SEC FILINGS
NO PINK NO. FILINGS
NO RECENT NEW ARTICLES
Technical Analysis:
In a timescale of years, the stock has been slowly increasing its pps (or price per share) from its two year low of 0.0001 on April 26, 2016, to its two year high of 0.0013 on 8/12/17. Between this period, the pps has been fairly volatile, moving between the 0.0004 region to the 0.0010 region. This seems to be the average range for the pps to fall between this time scale.
Read The Full Article Here!
Read Full Article Here
Business Information:
Jupiter Marine International Holdings Inc.
Ticker: JMIH
PPS: 0.0057 a/o 8/12/2017
Up 0.0027 or +89.70%
Market Value: $107,335 a/o August 11, 2017
Authorized Shares: Data Not Available
Outstanding Shares: 18,863,861 a/o Oct 20, 2006
Fundamental Analysis:
According to Reuters, Jupiter Marine International Holdings, Inc. (OTCPK:JMIH) is engaged in building offshore sport fishing boats. The company is focused on boat designing and development. The company’s manufacturing plant is located in the gulf coast of Florida. The company claims that it has many makes and models of boats to choose.
Jupiter Marines’ Management:
Mr. Carl M. Herndon Sr. CEO, Pres, Director, CEO of JMI, Pres of JMI and Director of JMI
Mr. Lawrence S. Tierney, Chief Operating Officer (COO), Chief Financial Officer (CFO), Vice President, Secretary, and Director
Statistics:
Market Cap (intraday): $107,36k
Price/Sales: 0.01
Beta: 10.45
52-Week High: 0.005691
52-Week Low: 0.003
50-Day Moving Average: 0.003
200-Day Moving Average: 0.003
NO SEC FILINGS
NO PINK NO. FILINGS
NO RECENT NEW ARTICLES
Read Full Article Here
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
Read Full Article Here
Papa Bello Enterprises, Inc. (PAPA) Forward-Looking Analysis
Read Full Article Here
Business Information:
Papa Bello Enterprises, Inc.
Ticker: PAPA
PPS: 0.0048 a/o 8/11/2017
Up 0.0023 or +92.00%
Market Value: $497,190 a/o August 11, 2017
Authorized Shares 200,000,000 a/o June 27, 2012
Outstanding Shares: 103,581,341 a/o Jun 30, 2012
Float: 32,841,420 a/o June 27, 2012
Read Full Article Here
Fundamental Analysis:
According to OTCMarkets, Papa Bello Enterprises (PAPA) owns and operates a diversified group of companies as majority owned subsidiaries. Papa also provides expansion tools and operational support services to growth-stage businesses. This includes branding, manufacturing, financing, distribution, as well as other business related planning aids.
Aptose Management:
Mr. Merle Ferguson Chairman, Chief Executive Officer (CEO) and President
Mr. Frank Pastore, Chief Operating Officer (COO) and Director of Franchise Sales and Training
Mr. Lawrence Feierstein, Vice President of Sales and Marketing
Mr. Sunit Saha, President of Papa Bello Pizza
Ms. Judy Schuler, Controller of Papa Bello Enterprises Inc. – Nevada
Statistics:
Beta: -3.88
52-Week High: 0.0049
52-Week Low: 0.0015
50-Day Moving Average: 0.0022
200-Day Moving Average: 0.0020
Average Volume (3 Months): 266.23k
Average Volume (10 Day): 189.12k
Read Full Article Here
This region between 0.017 to 0.02 seems to be the next area for consolidation to occur. The volatile fluxations will likely test these highs and lows, though the lows seem to be winning recently.
I disagree though only partially. I think the company is growing though slowly. The company definitely seems hell bent on growing though I think they're doing it in the wrong places, and throwing money to the wrong people.
Also, if they were to stop spending so much on administrative expenses (unless that was for the new building), then that would add to their overall profit. If they were to renegotiate their cost of sales with their suppliers, this could significantly increase the companies bottom line.
The company is alive, now it needs to keep itself secure for the unforeseen future.
Made some light changes and sources were added to help make the argument being stated more clear. Happy Reading!
Read Article Here!
Why are you looking at the yearly report. Sure, the company is growing in sales month after month, but cost of sales is practically a fixed percentage from the net revenue. When that is 67% of the revenue gone, I see a significant problem. Then when administrative expenses hit, the company is using this profit to grow. The labor costs are engh cause they don't have that many people hired. Now, with the many sub companies or subsidiaries the company has, and their efforts to try to make them worth something, this is turning out to be a huge money sink imo. If they saved the money and only focused on increasing sales, we'd be a much better financial situation.
RXMD themselves have stated they they see both companies as competitors as many people already go to them for their needs. This will be an large problem when then try to go national.
I completely agree. I think the answer is to get their cost of sales down.
Read The Article
Oh thought you were talking NASDAQ. A lot of that going around. Does RXMD have their filings in order for OTCQB?
Nice seeing you. It's true that they're getting their ducks in a row, but unless they start buying back shares or merging shares together, we won't meet the threshold to uplist.
Buy Quidel Corporation! Insane Upward Trend With Gains Of 25.35% (Article)
Quidel is at a three year high with a pps (price per share) of 34.12
Quidel announced that they have entered into a definitive agreement to acquire Alere Triages' Assets
Made ~$118,189,000 in Gross Profits
The Global Biotechnical Market was valued at $270.5 Billion in 2013
Analysts gave QDEL an average estimate of ~$241.32 million for the expected total revenue in 2018.
Quidel Corporation (QDEL) is a biotechnical company that develops, manufactures, and markets their diagnostic testing solutions for infectious diseases, women's' health products, and gastrointestinal diseases. From their research and development efforts, Quidel has a wide range of products to offer. To begin with, they just received FDA Clearance and CLIA waiver for their award winning point-of-car Sofia 2 Instrument which is used for the rapid detection of respiratory syncytial virus (RSB). Also, the company has recently also gotten FDA Clearance to market their Solana C. difficile Assay for the detection of Clostridium difficile-infection (CDI). Their other products include QuickVue influenza, QuickVue RSV, Quidel Molecular RXV, and much more.
On July 17, 2017, Quidel announced that they have entered into a definitive agreement to acquire Alere Triages' Assets. This will allow Quidel to distribute the Triage MeterPro products and BNP assays which brought the acquired company $197 million in revenue for 2016. This comes two months after Quidel completed an acquisition of InflammaDry(R) and AdenoPlus(R) Eye-Health Businesses. With Quidel acquiring so many companies, it is clear that the company is growing into a major player in the biotechnical market.
QDEL is on a clear upward trend following these news releases with no end in sight. Currently, QDEL is at a three year high with a pps (price per share) of 34.12. From 10/13/14, QDEL hit its high at the time of ~28.6 and then fell to its three year low of 14.16 on 2/15/16. From that date forward, the stock has enjoyed many volatile increases upward. With QDEL shattering its previous highest resistance line, the sky is currently the limit for this stock. With a gold cross spotted, QDEL is certainly enjoying a very bullish market.
Read More Here
Aptose Biosciences. Inc. Forward-Looking Analysis
There is much competition for Aptose to fight against in the “finding the cure for cancer” market. From a business perspective, having a drug that cures cancer will practically print money for them. For example, some treatments for cancer can cost from $3000 too much more. These drugs, depending on their effectiveness, can create profits in the $1 Billion+ region. Because of this, many institutions are putting funds into finding the cure for various forms of cancer. This market is contently changing with new discoveries being frequently made. From a business standpoint, you need to make a drug that is more efficient, more effective, and more cost-effective to sell to the public. Simply, if you make the better drug and sell it for cheaper, your business will gain the market.
Looking at Aptoses’ income statement, they have a running loss with $0 in revenue. For the first quarter of 2017, the company had a net loss of ~$4,355,000. Also, over the course of the last year, the company has had a net loss of ~$17,910,000. Unless the company can create and sell one of their cures, Aptose will continue to run at a loss. If the company was to sell one of their cures, it comes down to how effective and efficient the drug is. These medicines would help it penetrate a full cancer treatments market. There is the possibility that the drugs and treatments could sell very well, but there is serious doubt that such an event will happen.
Aptoses’ balance statement shows that it has ~11,958,000 in on hand cash Q1 2017. From what we were able to find, the company is gaining on-hand cash from selling company shares to investors. In total, Aptose has a total of ~$12,676,000 in assets for Q1 2017. For accounts payable, Aptose has ~$2,340,000 in current liabilities. For shareholders equity, investors of Aptose have ~$235,869,000 in shares. The accumulated deficit for investors is ~$247,877,000.
Read More Here
Buy Aptose Biosciences. Inc. (APTO) As Analysts Give Buy Rating With A Price Target Of $9 (X5.5 ROI)!
Analysts set a price target of $9 (%550 ROI)
Both Short Term and Long Term Plays Can Be Made
Cancer/Tumor Profiling Market is poised to reach $61.87 Billion Dollars by 2021
Aptose Biosciences. Inc. (APTO) is a biotechnical company that looks to find treatments for cancers such as acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS), and other hematologic malignancies. With their research, APTO has discovered a form of treatment known as (CG'806) which is undergoing testing currently. On June 8, 2017, the company was rated as neutral by Rodman & Renshaw, and more recently was rated by analysts as a buy with a price target of $9 (%550). This news follows after a long period of decline, and signals a trend reversal for the stock! There's even growth to be found here in the short term. Earlier this week, the stock managed to break above the major upward resistance line of $1.55. This signals a near term move to $2.34 which is a very profitable 51% increase. Technicals are indeed indicating that money is to be made here!
Fundamentals for Aptose Biosciences are showing continued interest in their research. Investors large and small are aiding to continue the noble work they are doing. APTO currently has a very manageable amount of debt, with most of the expenses being paid. Aptoses' balance statement shows that APTO has ~$11,958,000 in on-hand cash with a total of ~$12,676,000 in overall business assets. These numbers added with the increase of good news from the company regarding their treatments' lab results are signals that we might be nearing excellent company growth.
Read More Here
Progressive Car Inc. (RXMD) Marches On
Q2 has come to an end and investors are eager to see the numbers
RXMD continues to grow in net revenue
$788,000 in on hand cash at the end of Q1
A period of consolidation continues to plague the stock
A brief history of the stock as we know it
RXMD has finally finished another quarter and her investors are eager to see the further progress the company has made. Year over year, month after month, RXMD has been exceeding their growth goals. Looking at the First Quarterly Report from 2017, we see that their net sales are up ~23% with $4,847,663. Also, their gross profits are up ~70% with $1,578,960. RXMD significantly improved their net sales for the year with an overall increase of ~34% with $18,318,567.
RXMD has a very high cost of sales. Looking again at the First Quarterly Report we got in 2017, we see that the cost of sales to their general expenses eats up about ~89% of their gross profits. Investors have advocated that it finds new ways to cut down on the cost of sales, as this would add more financial security.
Read The Rest Here
Ughhh no. RXMD should strive to get that insane expense down as it'll increase their profit line as well as make them more stable when the market turns against them.
No business should be satisfied with just "breaking even." I'm sure most investor agree that just "breaking even" simply just won't do.
I agree that the machine helped, and I'm sure that the cost of the machine will pay for itself in time. I'm not complaining about the machine.
Just the cost of sales being too high. (Aka cost of materials)
Oh and the robot was added to decrease administrative expenses, and to allow enployees to focus on customer service.
Do me a solid
-> go to otcmarkets.com and search for RXMD.
-> go to their annual and quarterly report
-> look at their balance sheet.
Compare their net revenue to their cost of sales. Almost 90% of the money they make is taken away as the cost for raw materials. Once business and administration fees are taken out too, the company is left with maybe $100,000 to $150,000 in actual profit. That isn't far from the "breaking even point" especially considering they're making and spending millions quarterly.
Plus, if they could improve cost of sales by say, 5% to 10%, this company would show huge financial growth. I've been asking that the company renegotiates their cost or raw materials since they stopped diluting and turned operating profitable.
Until they get this serious flaw addressed in one way or another, I wouldn't buy. If they did get this addressed, I'd buy literally as much as I could.
Ps. They're answer is to sell nationally. Soooo... they want to increase their expenses even more!?! Are they nuts!?!?!
They just broke even. Are they that eager to become negative again? Sure they'd get an increase in sales, but would the increase of expenses justify it?
Sold at 0.04 and happy af I did XD
LOLOL! More like getting in at a pps where money can be made!!
They're continuing to waste money on a market campaign. They've paid with dilution in the past even when they had on hand cash, soooo probably not good news guys. The pump (dump) is real here XD
I'll buy in at 0.001 -0.0005 or lower. Pps is too high for dilution with no sales. RIP shareholders money here...
You were definitely right!
I believe this stock will rise up to the next resistance level, which is around the 2.5 region. Any shorts that buy in now might be in for a really nice surprise!!!
Honestly, for a publically traded company that doesn't have any revenue, this company is definitely looking great by the balance sheets standards!
There's a upward trend emerging her. Get your shares while they're hot :p
I wrote a great article/blog about this stock. I look forward to sharing it with all of you in the near future!
The hell is this????????
http://funleaks.ru/tag/minoborony/red-rock-defender.html
(Look near bottom)
You're insane :/
80 shares traded. Big day ;)
The way things are going, they probably pocketed it leaving investors to fend for themselves. RIP
It's because we all sold. Dilution plus awful sales from the q10.
RIP the MFST dream